Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis

Background Older people (aged ≥ 65 years) have distinctive challenges with medication adherence. However, adherence and persistence patterns among older statin users have not been comprehensively reviewed. Methods As part of a broader systematic review, we searched Medline, Embase, PsycINFO, CINAHL, Database of Abstracts of Reviews of Effects, CENTRAL, and the National Health Service Economic Evaluation Database through December 2016 for English articles reporting adherence and/or persistence among older statin users. Data were analyzed via descriptive methods and meta-analysis using random-effect modeling. Results Data from more than 3 million older statin users in 82 studies conducted in over 40 countries were analyzed. At 1-year follow-up, 59.7% (primary prevention 47.9%; secondary prevention 62.3%) of users were adherent (medication possession ratio [MPR] or proportion of days covered [PDC] ≥ 80%). For both primary and secondary prevention subjects, 1-year adherence was worse among individuals aged more than 75 years than those aged 65-75 years. At 3 and ≥10 years, 55.3% and 28.4% of users were adherent, respectively. The proportion of users persistent at 1-year was 76.7% (primary prevention 76.0%; secondary prevention 82.6%). Additionally, 68.1% and 61.2% of users were persistent at 2 and 4 years, respectively. Among new statin users, 48.2% were nonadherent and 23.9% discontinued within the first year. The proportion of statin users who were adherent based on self-report was 85.5%. Conclusions There is poor short and long term adherence and persistence among older statin users. Strategies to improve adherence and reduce discontinuation are needed if the intended cardiovascular benefits of statin treatment are to be realized.

[1]  B. Scientific Thinking Outside the Pillbox A System-wide Approach to Improving Patient Medication Adherence for Chronic Disease , 2009 .

[2]  Hassan Khan,et al.  Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. , 2013, European heart journal.

[3]  T. Brennan,et al.  Long-Term Cost-Effectiveness of Providing Full Coverage for Preventive Medications After Myocardial Infarction , 2015, Circulation. Cardiovascular quality and outcomes.

[4]  A. Jaffe,et al.  A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2015 .

[5]  John P A Ioannidis,et al.  More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. , 2014, JAMA.

[6]  Alexander Turchin,et al.  Accuracy of Electronically Reported “Meaningful Use” Clinical Quality Measures , 2013, Annals of Internal Medicine.

[7]  M. V. van Driel,et al.  Interventions to improve adherence to lipid-lowering medication. , 2016, The Cochrane database of systematic reviews.

[8]  A. Newman,et al.  The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. , 2009, Clinics in geriatric medicine.

[9]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[10]  B. Nordestgaard,et al.  Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. , 2016, European heart journal.

[11]  S. Daskalopoulou,et al.  Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. , 2014, Current pharmaceutical design.

[12]  M. Williamson,et al.  A national census of medicines use: a 24‐hour snapshot of Australians aged 50 years and older , 2011, The Medical journal of Australia.

[13]  Harlan M Krumholz,et al.  Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.

[14]  R. Huupponen,et al.  Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register. , 2015, Atherosclerosis.

[15]  K. Bhaskaran,et al.  Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data , 2016, British Medical Journal.

[16]  Michael J Pencina,et al.  Application of new cholesterol guidelines to a population-based sample. , 2014, The New England journal of medicine.

[17]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[18]  J. Ross,et al.  Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults , 2016, Circulation. Cardiovascular quality and outcomes.

[19]  R. Ofori-Asenso,et al.  Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review , 2017, JMIR research protocols.

[20]  Poor Adherence to Statin and Antihypertensive Therapies as Risk Factors for Fatal Stroke. , 2016, Journal of the American College of Cardiology.

[21]  Mahendra Patel,et al.  Medicines adherence: Involving patients in decisions about prescribed medicines and supporting adherence , 2009 .

[22]  R B Haynes,et al.  Interventions for enhancing medication adherence. , 2008, The Cochrane database of systematic reviews.

[23]  J. Higgins,et al.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, International Coaching Psychology Review.

[24]  J. Breslow,et al.  How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? , 2012, Current Atherosclerosis Reports.

[25]  N. Stone,et al.  Statins in Very Elderly Adults (Debate) , 2014, Journal of the American Geriatrics Society.

[26]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[27]  Joseph Hanlon,et al.  Clinical consequences of polypharmacy in elderly , 2014, Expert opinion on drug safety.

[28]  H. Naci,et al.  Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials , 2013, European journal of preventive cardiology.

[29]  M. Lemstra,et al.  Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. , 2012, The Canadian journal of cardiology.

[30]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[31]  M. Farkouh,et al.  Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event. , 2014, The American journal of cardiology.

[32]  Zhu Jialiang,et al.  Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression , 2022, Frontiers in Endocrinology.

[33]  J. Hey-Hadavi,et al.  Tolerability of atorvastatin in a population aged > or =65 years: a retrospective pooled analysis of results from fifty randomized clinical trials. , 2006, The American journal of geriatric pharmacotherapy.

[34]  Y. Kwan,et al.  Systematic review of the barriers affecting medication adherence in older adults , 2016, Geriatrics & gerontology international.

[35]  M. Dimatteo,et al.  Health Beliefs, Disease Severity, and Patient Adherence: A Meta-Analysis , 2007, Medical care.

[36]  P. Shankar Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. , 2009 .